Medpace (NASDAQ:MEDP) Stock Price Up 0.6%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s stock price traded up 0.6% during trading on Thursday . The company traded as high as $402.11 and last traded at $400.11. 52,823 shares changed hands during trading, a decline of 79% from the average session volume of 248,554 shares. The stock had previously closed at $397.86.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. Robert W. Baird boosted their price objective on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their price target for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. Guggenheim increased their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and upped their price objective for the company from $282.00 to $452.00 in a report on Thursday, February 15th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $443.00.

Medpace Stock Up 0.4 %

The company has a market cap of $12.16 billion, a price-to-earnings ratio of 40.02, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. The company’s 50-day moving average is $398.08 and its 200 day moving average is $330.45.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. Medpace’s quarterly revenue was up 17.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.27 earnings per share. Analysts predict that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the sale, the chief executive officer now directly owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The disclosure for this sale can be found here. Insiders sold a total of 204,442 shares of company stock valued at $82,702,867 over the last quarter. 20.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Medpace by 5.9% during the fourth quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock worth $783,626,000 after purchasing an additional 142,591 shares during the period. Riverbridge Partners LLC boosted its position in Medpace by 7.1% in the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock valued at $199,975,000 after buying an additional 43,197 shares during the period. Invesco Ltd. grew its stake in shares of Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after acquiring an additional 246,775 shares in the last quarter. TD Asset Management Inc increased its position in shares of Medpace by 195.2% during the fourth quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after acquiring an additional 308,816 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in Medpace by 312.6% in the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after purchasing an additional 319,210 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.